[HTML][HTML] Phase 3 trial of nemolizumab in patients with prurigo nodularis

SG Kwatra, G Yosipovitch, FJ Legat… - … England Journal of …, 2023 - Mass Medical Soc
Background Prurigo nodularis is a chronic, debilitating, and severely pruritic
neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist …

Chronic prurigo including prurigo nodularis: new insights and treatments

S Müller, C Zeidler, S Ständer - American Journal of Clinical Dermatology, 2024 - Springer
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the
presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated …

Basic mechanisms of itch

L Misery, O Pierre, C Le Gall-Ianotto… - Journal of Allergy and …, 2023 - Elsevier
Pruritus (or itch) is an unpleasant sensation leading to a desire to scratch. In the epidermis,
there are selective C or Aδ epidermal nerve endings that are pruriceptors. At their other …

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind …

H Sofen, R Bissonnette, G Yosipovitch… - …, 2023 - thelancet.com
Background Prurigo nodularis is a chronic skin disease characterised by intensely pruritic,
hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta …

Molecular mechanisms of pruritus in prurigo nodularis

Y Shao, D Wang, Y Zhu, Z Xiao, T Jin, L Peng… - Frontiers in …, 2023 - frontiersin.org
Pruritus is the most common symptom of dermatological disorders, and prurigo nodularis
(PN) is notorious for intractable and severe itching. Conventional treatments often yield …

Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study

H Olbrich, K Kridin, G Hernández, H Zirpel, CD Sadik… - Ebiomedicine, 2024 - thelancet.com
Background Prurigo nodularis (PN) presents with intensely itchy hard nodules. Despite
being limited to the skin, PN was noted to be associated with systemic diseases including …

Chronic prurigo: Insufficient disease control in spite of high healthcare usage.

MP Pereira, E Weisshaar… - Journal of the …, 2023 - search.ebscohost.com
Abstract (a) Number of ambulatory visits (n= 441), inpatient stays (n= 339) and inpatient stay
days (n= 166) per patient due to chronic prurigo in per cent and absolute numbers. y-axis …

A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis

MA Nilforoushzadeh, N Heidari, Y Ghane… - …, 2024 - Springer
Background Prurigo nodularis (PN) is a neuroimmunological skin disease. Severe itching is
the most challenging symptom which affects patients' quality of life. T helper 2-derived …

[HTML][HTML] Prurigo: review of its pathogenesis, diagnosis, and treatment

PR Criado, M Ianhez, RFJ Criado, J Nakano… - Anais Brasileiros de …, 2024 - Elsevier
Prurigo is a reactive, hyperplastic skin condition characterized by pruritic papules, plaques,
and/or nodules. The temporal classification includes acute/subacute and chronic disease (≥ …

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics

HJ Yook, JH Lee - International Journal of Molecular Sciences, 2024 - mdpi.com
Chronic pruritus that lasts for over 6 weeks can present in various forms, like papules,
nodules, and plaque types, with prurigo nodularis (PN) being the most prevalent. The …